On Feb. 20, 2023, results from a randomized clinical trial of Ivermectin in a higher-hose and longer duration do not support the use of ivermectin among outpatients with COVID-19.

In this double-blind, randomized, placebo-controlled platform trial that included 1432 US adults with COVID-19 during February 2022 to July 2022, the median time to sustained recovery was 11 days in the ivermectin group and 12 days in the placebo group. In this largely vaccinated (83%) population, the posterior probability that ivermectin reduced symptom duration by more than 1 day was less than 0.1%.